Celgene Mutual Funds | StatInvestor

Health Care & Life Sciences » Biotechnology | Celgene Corp.

Celgene Corp. | Mutual Funds

Mutual Funds that own Celgene Corp.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Vanguard Total Stock Market Index Fund

18,216,312

2.59%

75,410

0.23%

07/31/2018

Vanguard 500 Index Fund

12,800,271

1.82%

13,279

0.27%

07/31/2018

iShares Nasdaq Biotechnology ETF

8,196,362

1.17%

-107,184

7.9%

09/06/2018

SPDR S&P 500 ETF

7,818,633

1.11%

90,272

0.27%

09/06/2018

Vanguard Institutional Index Fund

6,837,064

0.97%

6,467

0.27%

07/31/2018

Government Pension Fund - Global (The)

6,381,095

0.91%

907,690

0.07%

12/31/2017

PowerShares QQQ Trust

6,068,664

0.86%

-23,715

0.77%

09/05/2018

Advisors Inner Circle - Edgewood Growth Fund

6,011,454

0.86%

391,320

04/30/2018

Vanguard Growth Index Fund

5,104,759

0.73%

-14,604

0.56%

07/31/2018

Fidelity Spartan 500 Index Fund

4,708,393

0.67%

55,536

0.27%

07/31/2018

About Celgene

View Profile

Address	86 Morris Avenue Summit New Jersey 07901 United States
Employees	-
Website	http://www.celgene.com
Updated	07/08/2019
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax.